Meridian Bioscience announces FDA clearance for innovative Curian® Shiga Toxin Assay

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) had granted clearance for the company’s new Curian® Shiga Toxin assay. This assay joins Curian HpSA® and Curian Campy as Meridian expands its Curian diagnostic platform to maintain leadership in the gastrointestinal disease testing market.

Foodborne illness is a severe global public health problem that causes 48 million people to get sick yearly and 128,000 hospitalizations from common bacterial agents like Campylobacter and E. coli.1 Meridian is expanding its foodborne immunofluorescent testing capabilities beyond Campylobacter by adding Shiga toxin to the Curian platform. Speedy diagnosis is essential with patients suspected of having a Shiga toxin-producing E. coli infection because the use of antibiotics for treatment can increase Shiga toxin release, leading to hemolytic uremic syndrome (HUS), a potentially life-threatening complication.

The Curian Shiga Toxin assay is designed for use with the Curian analyzer. The new assay is a rapid, qualitative, fluorescent immunoassay for the simultaneous detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test device. It is intended for use with cultures derived from human stool specimens to aid in diagnosing diseases caused by Shiga toxin-producing E. coli (STEC) infections, including non-O157 strains.

The immunofluorescent technology of the Curian platform provides an objective, rapid Shiga toxin result with an unmatched clinical sensitivity of 100% (Stx1), 100% (Stx2), and specificity of 99.4% (Stx1), 99.5% (Stx2) in prospective samples. Curian Shiga Toxin features a lower limit of detection than traditional rapid immunoassay testing. Combined with LIS connectivity, the Curian solution helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually based lateral flow test results.

“We are excited to continue the expansion of the Curian platform with this highly sensitive and specific assay.  Curian now features the broadest menu of GI tests on an immunoassay analyzer,”

Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics

Tony adds, “Curian Shiga Toxin has a market-leading three-step sample prep workflow and produces fast, objective results that can help laboratorians and clinicians provide an objective Shiga toxin diagnosis to get patients on the correct treatment and back on the road to wellness.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meridian Bioscience, Inc.. (2023, September 18). Meridian Bioscience announces FDA clearance for innovative Curian® Shiga Toxin Assay. News-Medical. Retrieved on June 20, 2024 from https://www.news-medical.net/news/20230918/Meridian-Bioscience-announces-FDA-clearance-for-innovative-Curianc2ae-Shiga-Toxin-Assay.aspx.

  • MLA

    Meridian Bioscience, Inc.. "Meridian Bioscience announces FDA clearance for innovative Curian® Shiga Toxin Assay". News-Medical. 20 June 2024. <https://www.news-medical.net/news/20230918/Meridian-Bioscience-announces-FDA-clearance-for-innovative-Curianc2ae-Shiga-Toxin-Assay.aspx>.

  • Chicago

    Meridian Bioscience, Inc.. "Meridian Bioscience announces FDA clearance for innovative Curian® Shiga Toxin Assay". News-Medical. https://www.news-medical.net/news/20230918/Meridian-Bioscience-announces-FDA-clearance-for-innovative-Curianc2ae-Shiga-Toxin-Assay.aspx. (accessed June 20, 2024).

  • Harvard

    Meridian Bioscience, Inc.. 2023. Meridian Bioscience announces FDA clearance for innovative Curian® Shiga Toxin Assay. News-Medical, viewed 20 June 2024, https://www.news-medical.net/news/20230918/Meridian-Bioscience-announces-FDA-clearance-for-innovative-Curianc2ae-Shiga-Toxin-Assay.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.